{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:20:15Z","timestamp":1773933615478,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Immunology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.humimm.2024.111227","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T22:46:27Z","timestamp":1736203587000},"page":"111227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of anti-SARS-CoV-2 RBD antibody response after booster dose of SpikoGen\u00ae in individuals with two previous doses of Sinopharm and its association with HLA-DR and -DQ alleles"],"prefix":"10.1016","volume":"86","author":[{"given":"Amir Hossein","family":"Hajijafary","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Somayeh","family":"Malekmohammad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Awat","family":"Feizi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peyman","family":"Bemani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.humimm.2024.111227_bb0005","doi-asserted-by":"crossref","first-page":"106054","DOI":"10.1016\/j.ijantimicag.2020.106054","article-title":"Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies","volume":"56","author":"Sharma","year":"2020","journal-title":"International journal of antimicrobial agents"},{"issue":"3","key":"10.1016\/j.humimm.2024.111227_bb0010","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nature reviews microbiology"},{"issue":"4","key":"10.1016\/j.humimm.2024.111227_bb0015","first-page":"334","article-title":"Comprehensive review of coronavirus disease 2019 (COVID-19)","volume":"43","author":"Chauhan","year":"2020","journal-title":"Biom. J."},{"issue":"10223","key":"10.1016\/j.humimm.2024.111227_bb0020","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.humimm.2024.111227_bb0025","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1016\/S1473-3099(20)30837-9","article-title":"Towards an accurate and systematic characterisation of persistently asymptomatic infection with SARS-CoV-2","volume":"21","author":"Meyerowitz","year":"2021","journal-title":"The Lancet infectious diseases"},{"key":"10.1016\/j.humimm.2024.111227_bb0030","first-page":"7","article-title":"239 experts with one big claim: the coronavirus is airborne. The","author":"Mandavilli","year":"2020","journal-title":"New York Times."},{"key":"10.1016\/j.humimm.2024.111227_bb0035","doi-asserted-by":"crossref","DOI":"10.1177\/11779322211025876","article-title":"Structure and function of major SARS-CoV-2 and SARS-CoV proteins","volume":"15","author":"Gorkhali","year":"2021","journal-title":"Bioinformatics and biology insights."},{"issue":"1","key":"10.1016\/j.humimm.2024.111227_bb0040","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41392-022-00884-5","article-title":"Structural biology of SARS-CoV-2: open the door for novel therapies","volume":"7","author":"Yan","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.humimm.2024.111227_bb0045","first-page":"192","article-title":"COVID-19: a review on precautions and self-protection","volume":"7","author":"Hasani","year":"2023","journal-title":"Journal of Iranian Medical Council"},{"issue":"13","key":"10.1016\/j.humimm.2024.111227_bb0050","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa2118691","article-title":"Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection","volume":"386","author":"Hall","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.humimm.2024.111227_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.576622","article-title":"The SARS-CoV-2 spike glycoprotein biosynthesis, structure, function, and antigenicity: implications for the design of spike-based vaccine immunogens","volume":"11","author":"Duan","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.humimm.2024.111227_bb0060","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.humimm.2024.111227_bb0065","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3390\/vaccines9080910","article-title":"Antibody responses to natural SARS-CoV-2 infection or after COVID-19 vaccination","volume":"9","author":"Altawalah","year":"2021","journal-title":"Vaccines"},{"issue":"7857","key":"10.1016\/j.humimm.2024.111227_bb0070","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.humimm.2024.111227_bb0075","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3390\/vaccines10020153","article-title":"Decline of anti-SARS-CoV-2 IgG antibody levels 6 months after complete BNT162b2 vaccination in healthcare workers to levels observed following the first vaccine dose","volume":"10","author":"\u0110akovi\u0107 Rode","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.humimm.2024.111227_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.876533","article-title":"Differences in SARS-CoV-2-specific antibody responses after the first, second, and third doses of BNT162b2 in na\u00efve and previously infected individuals: a 1-year observational study in healthcare professionals","volume":"13","author":"Ogri\u010d","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.humimm.2024.111227_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13337-022-00755-1","article-title":"A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges","volume":"33","author":"Rahman","year":"2022","journal-title":"Virusdisease"},{"key":"10.1016\/j.humimm.2024.111227_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00832","article-title":"Human leukocyte antigen (HLA) and immune regulation: how do classical and non-classical HLA alleles modulate immune response to human immunodeficiency virus and hepatitis C virus infections?","volume":"8","author":"Crux","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.humimm.2024.111227_bb0095","series-title":"Major Histocompatibility Complex: Antigen Processing and Presentation. Autoimmunity: From Bench to Bedside","author":"Cruz-Tapias","year":"2013"},{"key":"10.1016\/j.humimm.2024.111227_bb0100","series-title":"Introduction to T and B Lymphocytes. Autoimmunity: From Bench to Bedside","author":"Cano","year":"2013"},{"issue":"S6","key":"10.1016\/j.humimm.2024.111227_bb0105","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ajpa.1330280505","article-title":"HLA II: the emergence of the molecular model for the human major histocompatibility complex","volume":"28","author":"Williams","year":"1985","journal-title":"Am. J. Phys. Anthropol."},{"issue":"2","key":"10.1016\/j.humimm.2024.111227_bb0110","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3390\/vaccines11020404","article-title":"Associations of HLA polymorphisms with anti-SARS-CoV-2 spike and neutralizing antibody titers in Japanese rheumatoid arthritis patients vaccinated with BNT162b2","volume":"11","author":"Higuchi","year":"2023","journal-title":"Vaccines"},{"issue":"3","key":"10.1016\/j.humimm.2024.111227_bb0115","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3390\/vaccines10030402","article-title":"HLA class II polymorphism and humoral immunity induced by the SARS-CoV-2 mRNA-1273 vaccine","volume":"10","author":"Guti\u00e9rrez-Bautista","year":"2022","journal-title":"Vaccines"},{"issue":"40","key":"10.1016\/j.humimm.2024.111227_bb0120","doi-asserted-by":"crossref","first-page":"5940","DOI":"10.1016\/j.vaccine.2021.07.087","article-title":"Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection","volume":"39","author":"Li","year":"2021","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.humimm.2024.111227_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccmp.2021.100004","article-title":"COVAX-19\u24c7 vaccine: completely blocks virus transmission to non-immune individuals","volume":"1","author":"Chavda","year":"2021","journal-title":"Clinical Complementary Medicine and Pharmacology."},{"issue":"3","key":"10.1016\/j.humimm.2024.111227_bb0130","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/imm.13540","article-title":"Immunogenicity and safety of SpikoGen\u00ae, an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: a randomized placebo-controlled trial","volume":"167","author":"Tabarsi","year":"2022","journal-title":"Immunology"},{"key":"10.1016\/j.humimm.2024.111227_bb0135","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3389\/fimmu.2018.00754","article-title":"Role of C-reactive protein at sites of inflammation and infection","volume":"9","author":"Sproston","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.humimm.2024.111227_bb0140","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41387-018-0070-9","article-title":"Current formula for calculating body mass index is applicable to Asian populations","volume":"9","author":"Misra","year":"2019","journal-title":"Nutr. Diabetes"},{"key":"10.1016\/j.humimm.2024.111227_bb0145","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.bbrc.2020.10.108","article-title":"Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity","volume":"538","author":"Carrillo","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.humimm.2024.111227_bb0150","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41422-021-00590-x","article-title":"Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and variants of concern","volume":"32","author":"Ai","year":"2022","journal-title":"Cell Res."},{"issue":"11","key":"10.1016\/j.humimm.2024.111227_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.str.2020.10.001","article-title":"The architecture of inactivated SARS-CoV-2 with postfusion spikes revealed by cryo-EM and cryo-ET","volume":"28","author":"Liu","year":"2020","journal-title":"Structure"},{"issue":"1","key":"10.1016\/j.humimm.2024.111227_bb0160","doi-asserted-by":"crossref","first-page":"8582","DOI":"10.1038\/s41598-017-09119-y","article-title":"Delta inulin-based adjuvants promote the generation of polyfunctional CD4+ T cell responses and protection against mycobacterium tuberculosis infection","volume":"7","author":"Counoupas","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.humimm.2024.111227_bb0165","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jconrel.2018.09.006","article-title":"Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge","volume":"288","author":"Tomar","year":"2018","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.humimm.2024.111227_bb0170","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3390\/vaccines11020451","article-title":"Factors influencing antibody response to SARS-CoV-2 vaccination","volume":"11","author":"Kodde","year":"2023","journal-title":"Vaccines"},{"issue":"3","key":"10.1016\/j.humimm.2024.111227_bb0175","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.vaccine.2021.12.012","article-title":"Antibody response to second dose of the BNT162b2 mRNA vaccine in the first 12 weeks in South Korea: a prospective longitudinal study","volume":"40","author":"Kim","year":"2022","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.humimm.2024.111227_bb0180","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-057084","article-title":"Factors associated with anti-SARS-CoV-2 antibody titres 3 months post-vaccination with the second dose of BNT162b2 vaccine: a longitudinal observational cohort study in western Greece","volume":"12","author":"Parthymou","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.humimm.2024.111227_bb0185","series-title":"Adverse effects and antibody titers in response to the BNT162b2 mRNA COVID-19 vaccine in a prospective study of healthcare workers. Open Forum Infectious Diseases","year":"2022"},{"issue":"4","key":"10.1016\/j.humimm.2024.111227_bb0190","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3390\/vaccines10040601","article-title":"Higher antibody concentrations in US health care workers associated with greater reactogenicity post-vaccination","volume":"10","author":"Dickerson","year":"2022","journal-title":"Vaccines"},{"issue":"8","key":"10.1016\/j.humimm.2024.111227_bb0195","doi-asserted-by":"crossref","first-page":"825","DOI":"10.3390\/vaccines9080825","article-title":"Sex disparities in efficacy in COVID-19 vaccines: a systematic review and meta-analysis","volume":"9","author":"Bignucolo","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.humimm.2024.111227_bb0200","article-title":"RETRACTED: heterogeneous longitudinal antibody responses to Covid-19 mRNA vaccination. Clinical","volume":"14","author":"de la Monte","year":"2021","journal-title":"Pathology"},{"key":"10.1016\/j.humimm.2024.111227_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.802858","article-title":"Characterization of SARS-CoV-2-specific humoral and cellular immune responses induced by inactivated COVID-19 vaccines in a real-world setting","volume":"12","author":"Li","year":"2021","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.humimm.2024.111227_bb0210","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.jamda.2020.05.045","article-title":"The effect of age on mortality in patients with COVID-19: a meta-analysis with 611,583 subjects","volume":"21","author":"Bonanad","year":"2020","journal-title":"J. Am. Med. Dir. Assoc."},{"issue":"4","key":"10.1016\/j.humimm.2024.111227_bb0215","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3390\/vaccines10040512","article-title":"IgG antibody response to the Pfizer BNT162b2 SARS-CoV-2 vaccine in healthcare workers with healthy weight, overweight, and obesity","volume":"10","author":"Bates","year":"2022","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.humimm.2024.111227_bb0220","doi-asserted-by":"crossref","DOI":"10.1111\/irv.13078","article-title":"Antibody responses to COVID-19 vaccination in people with obesity: a systematic review and meta-analysis","volume":"17","author":"Ou","year":"2023","journal-title":"Influenza Other Respir. Viruses"},{"issue":"9","key":"10.1016\/j.humimm.2024.111227_bb0225","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1007\/s11695-022-06181-y","article-title":"Antibody response to SARS-CoV-2 vaccines in people with severe obesity","volume":"32","author":"Kara","year":"2022","journal-title":"Obes. Surg."},{"key":"10.1016\/j.humimm.2024.111227_bb0230","first-page":"00018","article-title":"Factors that influence the immune response to vaccination","volume":"32(2):10.1128\/cmr","author":"Zimmermann","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"issue":"4","key":"10.1016\/j.humimm.2024.111227_bb0235","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1086\/427558","article-title":"Human leukocyte antigen class II alleles and rubella-specific humoral and cell-mediated immunity following measles-mumps-rubella-II vaccination","volume":"191","author":"Ovsyannikova","year":"2005","journal-title":"J. Infect. Dis."},{"issue":"14","key":"10.1016\/j.humimm.2024.111227_bb0240","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000024904","article-title":"HLA-DPB1 alleles in hepatitis B vaccine response: a meta-analysis","volume":"100","author":"Ou","year":"2021","journal-title":"Medicine"},{"issue":"8","key":"10.1016\/j.humimm.2024.111227_bb0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071376","article-title":"Correlation between human leukocyte antigen class II alleles and HAI titers detected post-influenza vaccination","volume":"8","author":"Moss","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.humimm.2024.111227_bb0250","article-title":"Association between human leukocyte antigen and COVID-19 severity","volume":"400-5","author":"Hajebi","year":"2021","journal-title":"Acta Med. Iran."},{"issue":"10","key":"10.1016\/j.humimm.2024.111227_bb0255","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.humimm.2021.07.004","article-title":"HLA-DRB1* 04 may predict the severity of disease in a group of Iranian COVID-19 patients","volume":"82","author":"Ebrahimi","year":"2021","journal-title":"Hum. Immunol."},{"issue":"4","key":"10.1016\/j.humimm.2024.111227_bb0260","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/iji.12505","article-title":"A role for human leucocyte antigens in the susceptibility to SARS-Cov-2 infection observed in transplant patients","volume":"47","author":"Poulton","year":"2020","journal-title":"Int. J. Immunogenet."},{"issue":"4","key":"10.1016\/j.humimm.2024.111227_bb0265","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3390\/vaccines10040563","article-title":"An association study of HLA with the kinetics of SARS-CoV-2 spike specific IgG antibody responses to BNT162b2 mRNA vaccine","volume":"10","author":"Khor","year":"2022","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.humimm.2024.111227_bb0270","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41591-022-02078-6","article-title":"Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection","volume":"29","author":"Mentzer","year":"2023","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.humimm.2024.111227_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e28528","article-title":"Evaluation the frequencies of HLA alleles in moderate and severe COVID-19 patients in Iran: a molecular HLA typing study","volume":"10","author":"Abolnezhadian","year":"2024","journal-title":"Heliyon"},{"issue":"3","key":"10.1016\/j.humimm.2024.111227_bb0280","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jmii.2021.08.009","article-title":"Study of HLA-A,-B,-C,-DRB1 and-DQB1 polymorphisms in COVID-19 patients","volume":"55","author":"Guti\u00e9rrez-Bautista","year":"2022","journal-title":"J. Microbiol. Immunol. Infect."}],"container-title":["Human Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885924004907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885924004907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T21:12:31Z","timestamp":1740085951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0198885924004907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0198885924004907"],"URL":"https:\/\/doi.org\/10.1016\/j.humimm.2024.111227","relation":{},"ISSN":["0198-8859"],"issn-type":[{"value":"0198-8859","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of anti-SARS-CoV-2 RBD antibody response after booster dose of SpikoGen\u00ae in individuals with two previous doses of Sinopharm and its association with HLA-DR and -DQ alleles","name":"articletitle","label":"Article Title"},{"value":"Human Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humimm.2024.111227","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111227"}}